-+ 0.00%
-+ 0.00%
-+ 0.00%

Assembly Biosciences Q3 net loss more than doubles year over year to $20.26 million

PUBT·11/12/2026 21:01:21
Listen to the news
Assembly Biosciences Q3 net loss more than doubles year over year to $20.26 million
  • Assembly Biosciences’ third-quarter 2026 net loss more than doubled year over year to $20.26 million.
  • Revenue fell 73% year over year to $2.96 million, primarily due to a reduction in the HPI license transaction price.
  • A $75 million collaboration extension fee received from Gilead in November supports a projected cash runway into 2029.
  • Dosing began in a Phase 2 study of ABI-6250 for chronic hepatitis delta infection.
  • The company exercised its option for a 40% share of U.S. development costs and profits for the HSV helicase-primase inhibitor program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Assembly Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121600PRIMZONEFULLFEED9876789) on November 12, 2026, and is solely responsible for the information contained therein.